Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 8/20 | 0.61 |
| ▸ | MTNR1A | P48039 | 9/20 | 0.40 |
| ▸ | MTNR1B | P49286 | 5/20 | 0.40 |
| ▸ | NQO2 | P16083 | 1/20 | 0.40 |
| ▸ | ACACA | Q13085 | 4/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | DRD3 | P35462 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL648434 | 1.00 | ACACB (0.61) | ACACBMTNR1AMTNR1BNQO2ACACA | |
| SCHEMBL649521 | 0.92 | ACACB (0.61) | ACACBMTNR1AMTNR1BNQO2ACACA | |
| SCHEMBL649221 | 0.92 | ACACB (0.61) | ACACBMTNR1AMTNR1BNQO2ACACA | |
| SCHEMBL649220 | 0.92 | ACACB (0.61) | ACACBMTNR1AMTNR1BNQO2ACACA | |
| SCHEMBL649444 | 0.91 | ACACB (0.60) | ACACBMTNR1AMTNR1BNQO2ACACA | |
| SCHEMBL649910 | 0.91 | ACACB (0.60) | ACACBMTNR1AMTNR1BNQO2ACACA | |
| SCHEMBL649155 | 0.91 | ACACB (0.59) | ACACBMTNR1AMTNR1BNQO2ACACA | |
| SCHEMBL649154 | 0.91 | ACACB (0.59) | ACACBMTNR1AMTNR1BNQO2ACACA | |
| SCHEMBL650374 | 0.91 | ACACB (0.59) | ACACBMTNR1AMTNR1BNQO2ACACA | |
| SCHEMBL650375 | 0.91 | ACACB (0.59) | ACACBMTNR1AMTNR1BNQO2ACACA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8119687-B2 | Derivatives of dioxan-2-alkyl carbamates, preparation thereof and application thereof in therapeutics | SANOFI-AVENTIS (FR) | 2012-02-21 | — | — | US | disclosed |
| US-20100280076-A1 | DERIVATIVES OF DIOXAN-2-ALKYL CARBAMATES, PREPARATION THEREOF AND APPLICATION THEREOF IN THERAPEUTICS | SANOFI-AVENTIS (FR) | 2010-11-04 | — | — | US | disclosed |
| US-7777057-B2 | 2-Amino-2-oxoethyl trans-3-[5-(naphth-1-yl)-1,3-dioxan-2-yl]propyl carbamate; reacting the phenylcarbonate with 2-aminodioxane; fatty acid amido hydrolase (FAAH) inhibitors; analgesics; nervous system disorders; gastrointestinal disorders,; to name just a few | SANOFI-AVENTIS (FR) | 2010-08-17 | — | — | US | disclosed |
| US-20090286868-A1 | DERIVATIVES OF DIOXAN-2-ALKYL CARBAMATES, PREPARATION THEREOF AND APPLICATION THEREOF IN THERAPEUTICS | SANOFI-AVENTIS (FR) | 2009-11-19 | — | — | US | disclosed |
| EP-1537096-B1 | DERIVATIVES OF DIOXANE-2-ALKYL CARBAMATES, PREPARATION METHOD THEREOF AND APPLICATION OF SAME IN THERAPEUTICS | SANOFI AVENTIS (FR) | 2008-09-24 | — | — | EP | disclosed |
| EP-1840125-A2 | Derivatives of dioxane-2-alkyl carbamates, preparation thereof and application thereof in therapeutics | sanofi-aventis (FR) | 2007-10-03 | — | — | EP | disclosed |
| US-20060247290-A1 | DERIVATIVES OF DIOXAN-2-ALKYL CARBAMATES, PREPARATION THEREOF AND APPLICATION THEREOF IN THERAPEUTICS | SANOFI-AVENTIS (FR) | 2006-11-02 | — | — | US | disclosed |
| US-7119116-B2 | Derivatives of dioxane-2-alkyl carbamates, preparation thereof and application thereof in therapeutics | SANOFI-AVENTIS (FR) | 2006-10-10 | — | — | US | disclosed |
| US-20050182130-A1 | Derivatives of dioxane-2-alkyl carbamates, preparation thereof and application thereof in therapeutics | SANOFI AVENTIS (FR) | 2005-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100280076-A1 | DERIVATIVES OF DIOXAN-2-ALKYL CARBAMATES, PREPARATION THEREOF AND APPLICATION THEREOF IN THERAPEUTICS | CHRM3, CHRM2, CHRM4 | ACACB 829/4885MTNR1A 466/4885MTNR1B 1041/4885 |
| US-20060247290-A1 | DERIVATIVES OF DIOXAN-2-ALKYL CARBAMATES, PREPARATION THEREOF AND APPLICATION THEREOF IN THERAPEUTICS | CHRM3, CHRM2, CHRM4 | ACACB 829/4885MTNR1A 466/4885MTNR1B 1041/4885 |
| US-20050182130-A1 | Derivatives of dioxane-2-alkyl carbamates, preparation thereof and application thereof in therapeutics | CHRM3, CHRM2, CHRM4 | ACACB 681/4885MTNR1A 540/4885MTNR1B 1234/4885 |
| US-20090286868-A1 | DERIVATIVES OF DIOXAN-2-ALKYL CARBAMATES, PREPARATION THEREOF AND APPLICATION THEREOF IN THERAPEUTICS | CHRM3, CHRM2, CHRM4 | ACACB 829/4885MTNR1A 466/4885MTNR1B 1041/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.